ArticleBMC infectious diseases2026

Clinical and Pharmacoeconomic evaluation of Fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infection.

Isabella Alram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.